<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The occurrence of <z:hpo ids='HP_0002863'>Myelodysplastic Syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0011009'>Acute</z:hpo> Myeloblastic <z:mpath ids='MPATH_336'>Leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) following cytotoxic therapy for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic disease</z:e> is well recognised </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutations are common in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To determine whether these lesions are found as early markers of <z:e sem="disease" ids="C0277555" disease_type="Disease or Syndrome" abbrv="">secondary disease</z:e>, we have studied the incidence of <z:mp ids='MP_0011356'>RAS</z:mp> mutations in the peripheral blood of 70 patients in complete remission from <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were treated by standard chemotherapy regimes and/or localised radiotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment had been given 6 months to 14 1/2 years previously and no patient showed any sign of <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Genomic DNA from peripheral blood leukocytes was amplified in vitro at target codons of N, K and H <z:mp ids='MP_0011356'>RAS</z:mp> genes, and mutations detected by hybridisation with oligonucleotide probes </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutations were detected in 9 subjects </plain></SENT>
<SENT sid="7" pm="."><plain>One patient with an N12 valine (Val) substitution had been in complete remission from <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) for 9 years </plain></SENT>
<SENT sid="8" pm="."><plain>DNA from this patient registered in a <z:mp ids='MP_0003815'>nude</z:mp> mouse tumorigenicity assay (NMT) </plain></SENT>
<SENT sid="9" pm="."><plain>The N12 Val mutation was not detected in the original <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> tissue from the same patient </plain></SENT>
<SENT sid="10" pm="."><plain>A second patient in remission from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> showed evidence of co-existent N12 cysteine (Cys) and N13 valine (Val) substitutions which were not detected in presentation material or unaffected tissues </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients are currently haematologically <z:mpath ids='MPATH_458'>normal</z:mpath>, indicating that clones of mutant <z:mp ids='MP_0011356'>RAS</z:mp> bearing cells may be detected prior to any overt sign of disease </plain></SENT>
</text></document>